3 Other information

3.1 Scope and how this guideline was developed

NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover.

This guideline covers drug therapy for inducing and maintaining remission in people with mild to moderate and acute severe ulcerative colitis. Specific consideration is given to pregnant women with ulcerative colitis and the monitoring of bone health and growth and pubertal development in children and young people. The information needs of people considering surgery is also covered. The diagnosis of ulcerative colitis is not covered by this guideline.

How this guideline was developed

NICE commissioned the National Clinical Guideline Centre to develop this guideline. The Centre established a Guideline Development Group (see section 4), which reviewed the evidence and developed the recommendations.

The methods and processes for developing NICE clinical guidelines are described in The guidelines manual.

3.2 Related NICE guidance

Details are correct at the time of publication of the guideline (June 2013). Further information is available on the NICE website.

Published

General
Condition-specific
  • National Institute for Health and Care Excellence (NICE)